OSE Pharma SA (OSE) News
Track canonical SquawkNews coverage tagged to OSE, OSE Pharma SA. This hub brings together deduplicated headlines about nasdaqgs, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Lusvertikimab posts strong phase II ulcerative colitis results, advancing
Lusvertikimab, an anti-IL-7 receptor antibody, reported robust efficacy and safety in phase II ulcerative colitis trials, with consistent improvements across clinical, endoscopic and histological endpoints. Development i
EQUITY | Sep 02, 2026, 05:32 PM UTC
L
OSE Immunotherapeutics schedules KOL webcast on lusvertikimab Sept 2, 2026
OSE Immunotherapeutics will host a KOL webcast dedicated to lusvertikimab on September 2, 2026.
EQUITY | Aug 28, 2026, 05:37 AM UTC